A three-year supervised exercise programme after chemotherapy cut recurrence and death by roughly a third in 889 patients, an effect the size of adjuvant chemotherapy. No health system has a funding line for it.
CHALLENGE randomised 889 patients with resected colon cancer who had completed adjuvant chemotherapy to a structured exercise programme or health-education materials over three years. At a median 7.9 years, disease-free survival favoured exercise with a hazard ratio of 0.72 (five-year disease-free survival 80.3 against 73.9 percent), and overall survival with a hazard ratio of 0.63 (eight-year overall survival 90.3 against 83.2 percent). Musculoskeletal adverse events were more common with exercise (18.5 against 11.5 percent).
The trial took 15 years to enrol because no commercial sponsor benefits from the result, and the intervention is a supervised programme with a behaviour-support consultant rather than advice to be more active. That is the gap: the evidence is now stronger than for several funded drugs in the same setting, and the implementation question, who employs the trainers and how patients are referred, has never been tested in a health system.
Shares Structured exercise after adjuvant chemotherapy for colon cancer (CHALLENGE), Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Colon cancer (adenocarcinoma of the colon), Colorectal cancer and the tag colorectal-evidence.
Shares Prevention we already have is not deployed, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Colorectal cancer and the tag colorectal-evidence.
Shares Prevention we already have is not deployed, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Colorectal cancer and the tag colorectal-evidence.
Shares Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Colon cancer (adenocarcinoma of the colon), Colorectal cancer and the tag colorectal-evidence.
Shares Prevention we already have is not deployed, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Colon cancer (adenocarcinoma of the colon), Colorectal cancer and the tag colorectal-evidence.
Shares Prevention we already have is not deployed, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Colorectal cancer and the tag colorectal-evidence.
Shares Prevention we already have is not deployed, Colon cancer (adenocarcinoma of the colon), Colorectal cancer and the tag colorectal-evidence.
Shares Prevention we already have is not deployed, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Colorectal cancer and the tag colorectal-evidence.